BuSpar Generic Decision Favors Bristol: FDA Decision On ANDAs Pending

FDA may consider returning generic buspirone ANDA approvals to tentative approval status as one option in light of an appellate court decision favoring Bristol-Myers Squibb in the BuSpar patent case.